• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec8
Vaxcyte Inc. Initiates OPUS Phase 3 Clinical Trial for VAX-31 Pneumococcal Vaccine
12:00
Nov20
Mizuho Analyst Maintains Buy Rating on Vaxcyte
21:01
Nov10
BTIG Analyst Thomas Shrader Maintains Buy Rating on Vaxcyte with $85 Target Price
12:12
Nov5
Analyst Maintains Strong Buy Rating on Vaxcyte Stock
12:02
Vaxcyte released FY2025 Q3 earnings on November 4 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.5626 (forecast USD -1.31)
04:00
Vaxcyte released FY2025 9 Months earnings on November 4, 2025 (EST), actual revenue USD 0, actual EPS USD -3.8242
04:00

Schedules & Filings

Schedules
Filings
Nov4
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -212.83 M, EPS -1.5626

Aug6
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -166.57 M, EPS -1.2244

May7
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -140.72 M, EPS -1.037

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
ASPC
24.010
+78.91%
+10.590
PCLA
0.4050
+74.49%
+0.173
DTCK
0.3951
+66.08%
+0.157
SOPA
1.820
+58.26%
+0.670
ECDA
1.150
+46.50%
+0.365
GAUZ
1.470
+44.12%
+0.450
CELG.RT
0.0698
+39.60%
+0.020
ASPCR
0.2500
+38.89%
+0.070
PAVS
2.170
+37.34%
+0.590
CUE
0.3248
+34.77%
+0.084
View More